These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 22569908

  • 1. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
    Hall MD, Daly HL, Zhang JZ, Zhang M, Alderden RA, Pursche D, Foran GJ, Hambley TW.
    Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
    [Abstract] [Full Text] [Related]

  • 2. XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
    Hall MD, Foran GJ, Zhang M, Beale PJ, Hambley TW.
    J Am Chem Soc; 2003 Jun 25; 125(25):7524-5. PubMed ID: 12812486
    [Abstract] [Full Text] [Related]

  • 3. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH, al-Baker S, Thai G, Khokhar AR.
    Anticancer Drug Des; 1994 Apr 25; 9(2):139-51. PubMed ID: 8166929
    [Abstract] [Full Text] [Related]

  • 4. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
    Ali MS, Khan SR, Ojima H, Guzman IY, Whitmire KH, Siddik ZH, Khokhar AR.
    J Inorg Biochem; 2005 Mar 25; 99(3):795-804. PubMed ID: 15708801
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
    Liu W, Chen X, Xie M, Lou L, Ye Q, Yu Y, Hou S.
    J Inorg Biochem; 2008 Oct 25; 102(10):1942-6. PubMed ID: 18707762
    [Abstract] [Full Text] [Related]

  • 6. The preparation and characterization of trans-platinum(IV) complexes with unusually high cytotoxicity.
    Cubo L, Hambley TW, Sanz Miguel PJ, Carnero A, Navarro-Ranninger C, Quiroga AG.
    Dalton Trans; 2011 Jan 14; 40(2):344-7. PubMed ID: 20936210
    [Abstract] [Full Text] [Related]

  • 7. Platinum(II) oxalato complexes with adenine-based carrier ligands showing significant in vitro antitumor activity.
    Starha P, Trávnícek Z, Popa I.
    J Inorg Biochem; 2010 Jun 14; 104(6):639-47. PubMed ID: 20304500
    [Abstract] [Full Text] [Related]

  • 8. Analysis of cytotoxicities of platinum compounds.
    Goodisman J, Hagrman D, Tacka KA, Souid AK.
    Cancer Chemother Pharmacol; 2006 Jan 14; 57(2):257-67. PubMed ID: 16028101
    [Abstract] [Full Text] [Related]

  • 9. Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds.
    Ruiz J, Villa MD, Cutillas N, López G, de Haro C, Bautista D, Moreno V, Valencia L.
    Inorg Chem; 2008 Jun 02; 47(11):4490-505. PubMed ID: 18447329
    [Abstract] [Full Text] [Related]

  • 10. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z, Wang Z, Yiu SM, Zhu G.
    Dalton Trans; 2015 Dec 14; 44(46):19918-26. PubMed ID: 26514681
    [Abstract] [Full Text] [Related]

  • 11. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.
    J Control Release; 2008 Oct 21; 131(2):100-6. PubMed ID: 18691617
    [Abstract] [Full Text] [Related]

  • 12. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
    Mandal R, Kalke R, Li XF.
    Chem Res Toxicol; 2004 Oct 21; 17(10):1391-7. PubMed ID: 15487901
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
    Chen CK, Zhang JZ, Aitken JB, Hambley TW.
    J Med Chem; 2013 Nov 14; 56(21):8757-64. PubMed ID: 24107138
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.
    Ravera M, Gabano E, Zanellato I, Bonarrigo I, Escribano E, Moreno V, Font-Bardia M, Calvet T, Osella D.
    Dalton Trans; 2012 Mar 21; 41(11):3313-20. PubMed ID: 22286213
    [Abstract] [Full Text] [Related]

  • 16. Platinum complexes with 5-methyl-5(4-pyridyl)hydantoin and its 3-methyl derivatives: synthesis and cytotoxic activity - quantitative structure-activity relationships.
    Bakalova A, Varbanov H, Buyukliev R, Momekov G, Ivanov D, Doytchinova I.
    Arch Pharm (Weinheim); 2011 Apr 21; 344(4):209-16. PubMed ID: 21469169
    [Abstract] [Full Text] [Related]

  • 17. Kinetic study on the reactions of platinum drugs with glutathione.
    Hagrman D, Goodisman J, Souid AK.
    J Pharmacol Exp Ther; 2004 Feb 21; 308(2):658-66. PubMed ID: 14610218
    [Abstract] [Full Text] [Related]

  • 18. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
    Choi S, Vastag L, Larrabee YC, Personick ML, Schaberg KB, Fowler BJ, Sandwick RK, Rawji G.
    Inorg Chem; 2008 Feb 18; 47(4):1352-60. PubMed ID: 18220340
    [Abstract] [Full Text] [Related]

  • 19. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
    Cerè V, Grossi L, Munari D, Pollicino S, Martelli L, Martelli M.
    Anticancer Res; 2006 Feb 18; 26(3A):1815-9. PubMed ID: 16827112
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.